Bill of Health

JULY 1, 2022

Frequency, Characteristics, And Outcomes Of Negative Advisory Committee Votes For FDA-Approved Drugs. Fixing The FDA’s Orange Book. Coverage of New Drugs in Medicare Part D. The global impact of COVID-19 on drug purchases: A cross-sectional time series analysis. Health Aff (Millwood). 2022 May;41(5):713-721.

FDA 205

FDA COVID-19 Medicare Medicare 205

Bill of Health

MARCH 25, 2022

Experts’ Views on FDA Regulatory Standards for Drug and High-Risk Medical Devices: Implications for Patient Care. Medicaid Expenditures and Estimated Rebates on Line Extension Drugs, 2010-2018. 2022 Feb 19. Emergency Use Authorizations of COVID-19-Related Medical Products. 2022 Feb 24. Epub ahead of print.

FDA 205

FDA COVID-19 Medicaid Medicaid 205

C&M Health Law

JANUARY 25, 2023

Notably, the Act neither fulfilled the Biden Administration’s request for additional COVID-19 response funding nor included the Verifying Accurate Leading-edge In Vitro Clinical Test (IVCT) Development (VALID) Act, which proposed updating the current diagnostic testing regulatory framework.

Medicaid 104

Medicaid Medicaid Medicare Medicare 104

Kaiser Health News

JANUARY 12, 2023

But Medicare is likely to be on the agenda, which will require the input of the chairs of both committees. On one hand, the FDA has relaxed some of the risk evaluation and mitigation strategies (REMS) from the prescribing rules surrounding abortion pills. Some advocates say these pills simply do not bring that level or risk.

US Department of Health and Human Services 52

US Department of Health and Human Services FDA Medicare Medicare 52